Study guide
11.2 Confidentiality of Substance Use Disorder Patient Records: 42 CFR Part 2 (2024 Final Rule) & HIPAA Harmonization
Certified Addictions Registered Nurse - Advanced Practice CARN-AP
Track your progress as you read
Finished sections get a check mark.
1 Introduction: The CARN-AP Examination & Foundations of Advanced Addictions Practice
About the CARN-AP Examination: Blueprint, Scoring & Eligibility The Neurobiology of Addiction: Binge, Withdrawal & Preoccupation Screening, SBIRT & the ASAM Criteria Levels of Care
2 Chapter 1: Opioid Use Disorder: Assessment, Overdose Response & Methadone Maintenance
1.1 OUD Assessment, DSM-5-TR Diagnostic Criteria, and Clinical Opiate Withdrawal Scale (COWS) 1.2 Methadone Pharmacology, OTP Federal Regulations, QTc Prolongation & CYP450 Interactions 1.3 Opioid Overdose Assessment, Harm Reduction, Naloxone Formulations & Nalmefene
3 Chapter 2: Buprenorphine Protocols, Long-Acting Injectables & Naltrexone
2.1 Buprenorphine Pharmacology, Standard Office/Home Induction & Precipitated Withdrawal Management 2.2 Low-Dose Micro-Induction (Bernese Method) & Fentanyl Transition Strategies 2.3 Long-Acting Injectable Buprenorphine (Sublocade, Brixadi) & Extended-Release Naltrexone (Vivitrol)
4 Chapter 3: Alcohol Use Disorder: Neurobiology, Assessment & Acute Withdrawal
3.1 AUD Neurobiology, Epidemiology, Screening Instruments (AUDIT, AUDIT-C, CAGE) & Laboratory Biomarkers 3.2 Alcohol Withdrawal Syndrome, CIWA-Ar Protocol, Symptom-Triggered Benzodiazepine Regimens & Delirium Tremens 3.3 Wernicke-Korsakoff Syndrome, High-Dose Parenteral Thiamine Protocols & Acute Medical Complications
5 Chapter 4: Medications for Alcohol Use Disorder (MAUD)
4.1 Oral and Injectable Naltrexone for AUD: Mechanism, Prescribing Protocols & Clinical Efficacy 4.2 Acamprosate Calcium: NMDA Modulation, Renal Dosing Parameters & Abstinence Maintenance 4.3 Disulfiram and Second-Line / Off-Label MAUDs: Topiramate, Gabapentin & Baclofen
6 Chapter 5: Stimulant, Sedative-Hypnotic & Synthetic Substance Use Disorders
5.1 Stimulant Use Disorder (Cocaine & Methamphetamine): Neurotoxicity, Medical Emergencies & Evidence-Based Interventions 5.2 Sedative, Hypnotic, and Anxiolytic Disorders: Dependence Physiology, Risks & Outpatient Tapering Protocols 5.3 Emerging Synthetic Drugs: Fentanyl Analogues, Synthetic Cathinones, Cannabinoids & Xylazine-Associated Necrotic Wounds
7 Chapter 6: Tobacco and Cannabis Use Disorders: Evidence-Based Pharmacotherapy & Interventions
6.1 Tobacco Use Disorder & Nicotine Dependence: Dual NRT, Varenicline & Bupropion Prescribing Protocols 6.2 Cannabis Use Disorder, Synthetic Cannabinoids & Cannabinoid Hyperemesis Syndrome 6.3 Behavioral Therapies in Substance Use: Motivational Interviewing, CBT & Contingency Management
8 Chapter 7: Psychiatric Differential Diagnosis & Medical Mimics in Addictions
7.1 Diagnostic Formulation: Primary vs. Substance-Induced Psychiatric Disorders & The 30-Day Rule 7.2 Endocrine, Neurological, and Metabolic Mimics of Substance Intoxication and Withdrawal 7.3 Decisional Capacity, Competency, and Involuntary Commitment in Acute Addiction Practice
9 Chapter 8: Co-Occurring Psychiatric Disorders: Integrated Treatment Planning
8.1 Integrated Dual Diagnosis Treatment (IDDT) Framework & High-Prevalence Mood / Anxiety Co-Occurring Disorders 8.2 Complex Severe Mental Illness: Psychotic Disorders, Bipolar Disorder & Borderline Personality in Addictions 8.3 Trauma-Informed Care, PTSD, and Addictions: Evidence-Based Integrated Psychotherapy
10 Chapter 9: Pain Management in Substance Use Disorders & CDC 2022 Guidelines
9.1 CDC 2022 Clinical Practice Guideline for Prescribing Opioids for Chronic Pain: Individualized Assessment vs. Hard Caps 9.2 Multimodal Non-Opioid Pharmacotherapy, Interventional Modalities & Non-Pharmacological Strategies 9.3 Acute Pain Management in Patients on Maintenance MOUD (Methadone, Buprenorphine, Naltrexone)
11 Chapter 10: Perinatal Substance Use, Neonatal Abstinence & Infectious Complications
10.1 Perinatal Substance Use Disorder: ACOG/ASAM Guidelines, MOTHER Trial & Maintenance MOUD 10.2 Neonatal Abstinence Syndrome (NAS/NOWS): Finnegan Scoring vs. Eat, Sleep, Console (ESC) & Breastfeeding 10.3 Infectious Complications in People Who Inject Drugs: Viral Hepatitis, HIV, Endocarditis & PrEP/PEP
12 Chapter 11: Federal Regulations, Confidentiality & Controlled Substance Prescribing
11.1 Controlled Substances Act, DEA Registration, Schedule Classifications & MAT Act of 2023 11.2 Confidentiality of Substance Use Disorder Patient Records: 42 CFR Part 2 (2024 Final Rule) & HIPAA Harmonization 11.3 Prescription Drug Monitoring Programs (PDMP) & Urine Drug Testing (UDT) Interpretation
13 Chapter 12: APRN Scope of Practice, Ethical Foundations, Harm Reduction & Research Literacy
12.1 APRN Scope of Practice, Prescriptive Authority & Collaborative Practice Regulations 12.2 Ethical Dilemmas in Addictions Nursing: Stigma, Autonomy, Justice, and Maternal/Fetal Rights 12.3 Harm Reduction Philosophy, Syringe Service Programs, Drug Checking & Overdose Prevention 12.4 Landmark Clinical Trials & Research Literacy in Addictions Medicine
14 Chapter 13: Stimulant Use Disorder in Depth — Methamphetamine, Withdrawal, Treatment & Harm Reduction
13.1 Methamphetamine Use Disorder: Pharmacology, Medical & Psychiatric Sequelae 13.2 Stimulant Withdrawal, Craving & Contingency Management 13.3 Pharmacotherapy Research for Stimulant Use Disorder 13.4 Stimulant Harm Reduction, Overamping & Patient Education
15 Chapter 14: Medical Consequences of Alcohol Use — Liver, Heart, Cancer & Nutrition
14.1 Alcohol-Associated Liver Disease: Staging, Scoring & Management 14.2 Cardiovascular, Oncologic & Nutritional Consequences of Alcohol
16 Chapter 15: Brief Intervention, Drinking Goals & Recovery Support in Alcohol Use Disorder
15.1 Brief Intervention, Drinking Goals & Shared Decision Making in AUD 15.2 Relapse Prevention, Mutual-Help Programs & Recovery Support
17 Chapter 16: Tobacco Use Disorder in Depth — Neurobiology, Assessment & Special Populations
16.1 Nicotine Neurobiology, Epidemiology & the Tobacco Product Landscape 16.2 Tobacco Assessment & Behavioral Treatment: 5 A's, Quitlines & Incentives 16.3 Tobacco Treatment in Special Populations & Co-Occurring Disorders
18 Chapter 17: Cannabis Use Disorder in Depth — Products, Treatment & Policy
17.1 Cannabinoid Pharmacology, Potency & the Modern Product Landscape 17.2 Cannabis Use Disorder: Epidemiology, Assessment & Treatment Evidence 17.3 Medical Cannabis, Legalization Policy, Adolescent Risk & Patient Education
19 Chapter 18: Other Use Disorders — Inhalants, Hallucinogens, Process Addictions & Prescription/OTC Misuse
18.1 Inhalant Use Disorder: Volatile Solvents, Nitrous Oxide & Alkyl Nitrites 18.2 Hallucinogens & Dissociatives: Classic Psychedelics, PCP, Ketamine & HPPD 18.3 Process (Behavioral) Addictions: Gambling Disorder, Gaming & Compulsive Behaviors 18.4 Prescription & Over-the-Counter Substance Misuse: Opioids, Stimulants, Kratom & DXM
20 Chapter 19: Educating Patients, Families & the Public (CARN-AP Activity Area III)
19.1 Designing Health Teaching: Literacy, Readiness, Culture & Teach-Back 19.2 Medication Education, Informed Consent & Informed Refusal 19.3 Family & Support-System Education: CRAFT, Al-Anon & Overdose Prevention Teaching 19.4 Public, Professional & Anticipatory Guidance: Prevention and Advocacy Teaching
21 Chapter 20: Consultation, Collaboration & Care Coordination (CARN-AP Activity Area IV)
20.1 The APRN Consultation Process & Communicating Recommendations 20.2 Interprofessional Collaboration, Care Coordination & Transitions of Care 20.3 Community Resources, Systems Navigation & Collaborative Documentation
22 Chapter 21: Quality Improvement, Evidence & Leadership in Addictions Nursing (CARN-AP Activity Area V)
21.1 Outcome Measurement & Continuous Quality Improvement in Addictions Care 21.2 Policy Advocacy, Leadership & the Determinants of Addiction
11.2 Confidentiality of Substance Use Disorder Patient Records: 42 CFR Part 2 (2024 Final Rule) & HIPAA Harmonization
Key Takeaways Explain This Topic AI
42 CFR Part 2 protects the confidentiality of substance use disorder patient records created by federally assisted specialized Part 2 programs, shielding patients from legal and social stigma.
The 2024 Final Rule harmonizes Part 2 with HIPAA pursuant to the CARES Act, allowing a single general consent for all Treatment, Payment, and Health Care Operations (TPO).
Once disclosed to a HIPAA covered entity under a valid TPO consent, Part 2 records may be re-disclosed in accordance with standard HIPAA privacy rules.
The 2024 Final Rule integrates the HIPAA Breach Notification Rule and modern civil money penalties enforced by the HHS Office for Civil Rights (OCR).
Strict legal safeguards remain unchanged: Part 2 records cannot be used in civil, criminal, administrative, or legislative proceedings without a specialized court order upon showing of good cause.
Last updated: September 2026
11.2 Confidentiality of Substance Use Disorder Patient Records: 42 CFR Part 2 (2024 Final Rule) & HIPAA Harmonization
Core Clinical Competency: The Advanced Practice Registered Nurse (APRN) must navigate the intricate intersection of federal privacy mandates governing substance use disorder (SUD) patient records, distinguishing between general HIPAA privacy standards and specialized 42 CFR Part 2 protections, while applying the modernized 2024 Final Rule flexibilities to facilitate safe care coordination without compromising vital patient legal protections.
1. Statutory Foundations & The "Part 2 Program" Definition
Originally enacted by Congress in the 1970s under the Drug Abuse Prevention, Treatment, and Rehabilitation Act and codified at 42 U.S.C. § 290dd-2 , the federal regulations known as 42 CFR Part 2 ("Confidentiality of Substance Use Disorder Patient Records") were established to address a critical public health vulnerability: individuals with substance use disorders frequently avoid life-saving treatment due to pervasive fears that their medical records will be weaponized against them in criminal prosecutions, child custody disputes, employment terminations, or housing evictions.
What Constitutes a "Part 2 Program"?
Part 2 does not apply universally to every healthcare interaction involving substance use. It applies specifically to identifying information regarding patients diagnosed, treated, or referred for SUD by a federally assisted "Part 2 program." A healthcare entity qualifies as a Part 2 program only if it meets a two-prong statutory test: Statutory Definition of a 42 CFR Part 2 Entity:
- Prong 1: "Program" Functionality
- An individual practitioner whose primary practice is SUD diagnosis, treatment, or referral; OR
- An identified SUD unit within a general medical facility (e.g., an addiction consult team or detox unit);
- Medical personnel/staff whose primary function is the provision of SUD services.
- +
- Prong 2: "Federal Assistance"
- Receives federal grant funding or Medicaid/Medicare reimbursement; OR
- Holds federal tax-exempt non-profit status (501(c)(3)); OR
- Possesses a DEA registration to dispense controlled substances for OUD (e.g., OTP or methadone clinic); OR
- Is conducted, regulated, or operated directly by the federal government (e.g., Veterans Health Administration).
Clinical Distinction: General Medical Settings vs. Part 2 Programs
General Primary Care or Emergency Department: A general outpatient clinic, hospital emergency room, or primary care nurse practitioner who diagnoses an OUD and prescribes buprenorphine as part of general medical care is NOT a Part 2 program, provided the practice does not hold itself out to the public as primarily an SUD treatment facility and has no segregated SUD treatment unit. Records generated in this general setting are governed exclusively by HIPAA .
Specialized Opioid Treatment Program (OTP) or Addiction Clinic: A specialized outpatient clinic or inpatient addiction recovery center that advertises itself as an addiction treatment center and receives federal assistance is a Part 2 program . Records originating from this facility are governed by 42 CFR Part 2 .
2. The 2024 Final Rule: Modernization & HIPAA Harmonization
For decades, 42 CFR Part 2 operated under rigid disclosure restrictions that required granular, entity-specific written patient consent for almost every clinical information exchange. This created severe operational silos between addiction medicine and general healthcare, hindering electronic health record (EHR) integration, care coordination in Accountable Care Organizations (ACOs), and patient safety checks (such as medication reconciliation to prevent fatal opioid-sedative interactions).
To eliminate these dangerous care silos, Congress enacted Section 3221 of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020 , directing the Department of Health and Human Services (HHS) to align Part 2 confidentiality protections with the Health Insurance Portability and Accountability Act (HIPAA) Privacy, Security, and Breach Notification Rules.
In February 2024 , HHS—through the Substance Abuse and Mental Health Services Administration (SAMHSA) and the Office for Civil Rights (OCR)—issued the 2024 Final Rule (effective April 2024, with mandatory compliance across covered entities required by February 2026 ). This historic rulemaking modernized Part 2 while strictly maintaining core anti-discrimination and civil/criminal protections. Evolution of 42 CFR Part 2 Disclosure Architecture:
Pre-2024 Rule (Granular Consent Model):
- [Patient] ──► Explicit Consent ──► [Hospital A Only] ──► Re-disclosure PROHIBITED to Hospital B
- *Result: Fragmented records, clinical blind spots, EHR segmentation barriers*
2024 Final Rule Post-CARES Act (Unified TPO Model):
- [Patient] ──► Single General TPO Consent ──► [HIPAA Covered Entities & Business Associates]
- *Result: Permitted for all Treatment, Payment & Health Care Operations under HIPAA rules until revoked*
- Key Structural Modernizations of the 2024 Final Rule
Regulatory Dimension Historical 42 CFR Part 2 Framework Modernized 2024 Final Rule (HIPAA Alignment)
Consent for Treatment, Payment & Operations (TPO) Required granular, explicit written consent naming each specific individual, clinic, or third-party payer for every single disclosure. Single Broad Consent: Patients can sign a single, unified consent permitting future uses and disclosures of Part 2 records for all Treatment, Payment, and Health Care Operations (TPO) activities until revoked in writing.
Re-Disclosure Flexibilities Strict re-disclosure prohibition: any recipient of Part 2 records could not re-disclose information without obtaining a brand-new written consent from the patient. HIPAA-Standard Re-Disclosure: Once a Part 2 record is disclosed to a HIPAA covered entity or business associate pursuant to a general TPO consent, that entity may further re-disclose the record in full accordance with HIPAA privacy regulations (except in legal proceedings).
Breach Notification Mandate No formalized federal breach notification mechanism existed within Part 2 regulations. HIPAA Breach Notification Alignment: Directly applies 45 CFR Part 164, Subpart D . Programs must notify affected patients and the HHS Secretary within 60 days following discovery of an unsecured breach, and alert major media for breaches affecting ≥500 individuals.
Penalties & Enforcement Outdated criminal fines enforced exclusively by the Department of Justice ($500 initial fine, $5,000 subsequent fine; rarely prosecuted). Civil Money Penalties (CMP): Replaces criminal fines with HIPAA civil enforcement tiers under HHS Office for Civil Rights (OCR) , ranging from $100 to over $1,500,000 annually based on culpability.
Notice of Privacy Practices (NPP) Standalone, specialized Part 2 confidentiality notice required. Unified NPP: Establishes aligned Notice of Privacy Practices clearly explaining dual protections under both HIPAA and 42 CFR Part 2, including patient rights.
Patient Request for Restrictions No formal right under Part 2 to request restrictions on disclosures. Right to Request Restrictions: Aligns with HIPAA § 164.522; patients may request restrictions on disclosures for TPO and have the right to request an accounting of disclosures.
3. Strict Unchanged Legal Safeguards: Court Orders & Subpoenas
While the 2024 Final Rule significantly streamlined clinical communication for medical care, Congress and HHS made it unequivocally clear that legal and criminal protections surrounding SUD records were NOT weakened .
Absolute Prohibition on Legal Weaponization (Subpart E)
Under 42 U.S.C. § 290dd-2 and 42 CFR Part 2 Subpart E , no Part 2 record, testimony, or information—whether obtained directly, through re-disclosure, or from an integrated EHR—may be used in any criminal investigation, civil lawsuit, administrative proceeding, or legislative hearing against the patient, unless authorized by a specialized court order upon a formal showing of "good cause."
Critical Legal Distinction: A patient's signing of a general HIPAA TPO consent form DOES NOT authorize the release of their SUD treatment records to law enforcement, prosecutors, divorce attorneys, civil litigants, or administrative licensing boards. TPO consent applies exclusively to medical treatment, billing/payment, and healthcare operations.
The Subpoena vs. Court Order Rule
In general medical care under HIPAA, an attorney or law enforcement officer can obtain medical records simply by serving a valid legal subpoena accompanied by proof of notice. Under 42 CFR Part 2, a subpoena alone is legally worthless and unenforceable. Legal Mandate for Law Enforcement Access to Part 2 Records:
[Subpoena Alone] ──► UNLAWFUL! Must refuse disclosure.
[Court Order Alone] ──► INCOMPLETE! Compels nothing by itself.
[Subpoena + Part 2 Court Order] ──► LAWFUL! Disclosure legally authorized.
Stringent Judicial Criteria for a Part 2 Court Order
To obtain a valid Part 2 authorizing court order (under 42 CFR §§ 2.64–2.67), law enforcement or an adverse party must petition a court of competent jurisdiction and satisfy extraordinary legal thresholds:
Good Cause Determination: The court must determine that the public interest and the need for disclosure dramatically outweigh the potential injury to the patient, to the physician-patient relationship, and to the treatment services.
Extreme Crime Standard: For criminal investigations, the suspected crime must be an extremely serious crime (e.g., homicide, kidnapping, armed robbery, sexual assault). Part 2 records can never be released to investigate minor misdemeanors or simple illicit drug possession.
Exhaustion of Alternative Means: The petitioner must demonstrate that the required evidence cannot be obtained through any other reasonable investigative avenue.
Limitation & In-Camera Review: The court must limit disclosure strictly to those portions of the record essential to the objective, redact all extraneous notes, and conduct an in-camera review. Records must be kept under seal.
4. Operationalizing Part 2 in Advanced Nursing Practice
Advanced Practice Registered Nurses must ensure that daily clinical workflows uphold both HIPAA and Part 2 standards:
Consent Management & Patient Autonomy
Revocation Rights: Patients hold the absolute legal right to revoke their TPO consent at any time, verbally or in writing. Once revoked, future disclosures must halt immediately (disclosures made prior to revocation remain legally protected).
Accounting of Disclosures: Patients who sign a broad TPO consent are entitled under the CARES Act to receive an accounting of all disclosures made by the entity through an electronic health record during the preceding three years.
Medical Emergencies (42 CFR § 2.51): Patient identifying information may be disclosed to medical personnel without patient consent only to the extent necessary to treat a condition that poses an immediate threat to the health of any individual and requires immediate medical intervention (e.g., acute overdose resuscitation, active delirium tremens, emergency resuscitation).